Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H33N3O4 |
Molecular Weight | 379.4937 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1
InChI
InChIKey=JOATXPAWOHTVSZ-UHFFFAOYSA-N
InChI=1S/C20H33N3O4/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26)
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugs.com/international/celiprolol.html |
https://www.ncbi.nlm.nih.gov/pubmed/20825986 |
http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3466.1984.tb00456.x/abstract
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/celiprolol.html |
https://www.ncbi.nlm.nih.gov/pubmed/20825986 |
http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3466.1984.tb00456.x/abstract
Celiprolol is beta blocker, used to treat high blood pressure. Celiprolol is a selective β1 receptor antagonist, β2 receptor partial agonist. Celiprolol is not approved by the FDA, but is available worldwide under brand names Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm. It is used to treat mild to moderate hypertension and angina prectoris. In 2010 celiprolol has demonstrated positive results in the prevention of vascular complications of Ehlers-Danlos syndrome. Celiprolol has fewer CNS-related side effects than other beta blockers presumably because of limited penetration through blood-brain barrier because of its solubility.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL213 |
0.35 nM [Ki] | ||
Target ID: CHEMBL210 |
2.8 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | SELECTOL Approved UseCeliprolol is a vasodilating beta-1 selective adrenoceptor antagonist with partial beta-2 agonist activity. The beta-2 agonist activity is thought to account for its mild vasodilating and positive inotropic properties. It lowers the blood pressure in hypertensive patients at rest and exercise. The effects on heart rate and cardiac output are dependent on the pre-existing background level of sympathetic tone. |
|||
Primary | SELECTOL Approved UseCeliprolol is a vasodilating beta-1 selective adrenoceptor antagonist with partial beta-2 agonist activity. The beta-2 agonist activity is thought to account for its mild vasodilating and positive inotropic properties. It lowers the blood pressure in hypertensive patients at rest and exercise. The effects on heart rate and cardiac output are dependent on the pre-existing background level of sympathetic tone. |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-ischemic effects of celiprolol in patients with exercise-induced angina pectoris. | 1989 Oct |
|
[Pharmacological studies of celiprolol: III. Effects of celiprolol on the cardiovascular system and renal function, and its antiarrhythmic effects]. | 1990 Apr |
|
[Pharmacological studies of celiprolol: I. Beta-blocking effect, intrinsic sympathomimetic activity, vasodilating and hypotensive effects]. | 1990 Apr |
|
Celiprolol-induced lupus-like syndrome. | 2006 Dec |
|
[Vascular Ehlers-Danlos syndrome]. | 2006 Dec |
|
[Identification of blockers of adrenergic beta-receptors by thin layer chromatography]. | 2006 Jan |
|
Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. | 2006 Jan 15 |
|
Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. | 2006 Jan 25 |
|
Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study). | 2006 Jun |
|
Concurrent dolichoectasia of basilar and coronary arteries. | 2006 May 9 |
|
Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. | 2007 |
|
Celiprolol, a selective beta1-blocker, reduces the infarct size through production of nitric oxide in a rabbit model of myocardial infarction. | 2007 Apr |
|
Separation of beta-receptor blockers and analogs by capillary liquid chromatography (CLC) and pressurized capillary electrochromatography (pCEC) using a vancomycin chiral stationary phase column. | 2007 Aug |
|
Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. | 2007 Jan |
|
beta1 antagonist and beta2 agonist, celiprolol, restores the impaired endothelial dependent and independent responses and decreased TNFalpha in rat with type II diabetes. | 2007 Jan 16 |
|
Celiprolol reduces the intimal thickening of autogenous vein grafts via an enhancement of nitric oxide function through an inhibition of superoxide production. | 2007 Jul |
|
Ehlers-Danlos syndrome type IV. | 2007 Jul 19 |
|
Metabolic syndrome: treatment of hypertensive patients. | 2007 Jul-Aug |
|
[The inhibitory effect of pluronic on P-glycoprotein drug pump]. | 2007 Sep |
|
Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. | 2007 Spring |
|
Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers. | 2008 |
|
Carvedilol in hypertension treatment. | 2008 |
|
Hesperidin in orange juice reduces the absorption of celiprolol in rats. | 2008 Apr |
|
Immune defects in Alzheimer's disease: new medications development. | 2008 Dec 3 |
|
Ozonation of reverse osmosis concentrate: kinetics and efficiency of beta blocker oxidation. | 2008 Jun |
|
Simultaneous separation of eight beta-adrenergic drugs using titanium dioxide nanoparticles as additive in capillary electrophoresis. | 2008 Jun |
|
Natural and synthetic polymers as inhibitors of drug efflux pumps. | 2008 Mar |
|
Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. | 2008 May 22 |
|
Direct determination of celiprolol in human urine using on-line coupled ITP-CZE method with fiber-based DAD. | 2008 Nov |
|
American College of Endocrinology Pre-Diabetes Consensus Conference: part two. | 2008 Nov |
|
Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy. | 2008 Oct 13 |
|
Effects of the antioxidative beta-blocker celiprolol on endothelial progenitor cells in hypertensive rats. | 2008 Sep |
|
Chiral separation of beta-adrenergic blockers on CelluCoat column by HPLC. | 2009 Apr 30 |
|
Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits. | 2009 Dec |
|
Analysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides. | 2009 Dec |
|
Acute pulmonary edema due to stress cardiomyopathy in a patient with aortic stenosis: a case report. | 2009 Dec 2 |
|
Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. | 2009 Jul |
|
The role of transporters in the pharmacokinetics of orally administered drugs. | 2009 Sep |
|
Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. | 2009 Sep |
|
[Endothelial dysfunction: role of vasodilating betablockers in hypertension and chronic heart failure]. | 2010 Apr |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Fate of beta blockers in aquatic-sediment systems: sorption and biotransformation. | 2010 Feb 1 |
|
Chiral separations of some beta-adrenergic agonists and antagonists on AmyCoat column by HPLC. | 2010 Jan |
|
Highly sensitive transient isotachophoresis sample stacking coupling with capillary electrophoresis-amperometric detection for analysis of doping substances. | 2010 Jun 15 |
|
Evaluation of left atrial volumes using multidetector computed tomography: comparison with echocardiography. | 2010 May-Jun |
|
Human health risk assessment of pharmaceuticals in water: issues and challenges ahead. | 2010 Nov |
|
Fruit juice inhibition of uptake transport: a new type of food-drug interaction. | 2010 Nov |
|
Positive influence of AT(1) receptor antagonism upon the impaired celiprolol-induced vasodilatation in aorta from spontaneously hypertensive rats. | 2010 Oct 10 |
|
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. | 2010 Oct 30 |
|
Celiprolol therapy for vascular Ehlers-Danlos syndrome. | 2010 Oct 30 |
Patents
Sample Use Guides
The route of administration is oral. The usual dose in adults is 200 mg once daily in the morning. In the case of an inadequate response the dose may be increased to 400 mg daily. It is important to take Selectol one hour before or two hours after food with a glass of water. If the treatment is to be discontinued, reduce the dosage gradually over a period of 1-2 weeks. In hypertensive patients, additional treatment with other anti-hypertensive agents according to clinical guidelines is possible, in particular with diuretics. When a combination is initiated an increased monitoring of the blood pressure is recommended.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7858847
In order to quantify the affinity constants and potential partial agonist properties of beta-adrenoceptor antagonists at beta1-and beta2-adrenoceptors, competitive experiments for binding of [125I]-iodocyanopindolol (specific activity 2000 Cimmol-1) to beta-adrenoceptors were performed. Specific binding was defined as the difference in binding in the absence and in the presence of propranolol (3 umol^-1). Celiprolol at increasing concentrations (0.0001-100 umol-1) was used for binding experiments with lung, and with myocardial tissue. The experiments were performed in the presence and absence of Gpp(NH)p to evaluate agonist properties of the beta-adrenoceptor antagonists by changing the agonist affinity state of the binding site in the presence of the metabolically stable guanine nucleotide.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC07AB08
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
456714
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
||
|
WHO-ATC |
C07AB08
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
||
|
NCI_THESAURUS |
C29576
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m3232
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
3979
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
2663
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
56980-93-9
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
SUB07436MIG
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
D017272
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
DB04846
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
DTXSID3020259
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL27810
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
DRB57K47QC
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
Celiprolol
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
569
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
260-497-7
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
100000082044
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
C79558
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | |||
|
20498
Created by
admin on Fri Dec 15 16:12:29 GMT 2023 , Edited by admin on Fri Dec 15 16:12:29 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)